<DOC>
	<DOCNO>NCT02898077</DOCNO>
	<brief_summary>The purpose study evaluate efficacy study drug know ramucirumab participant gastric gastroesophageal cancer .</brief_summary>
	<brief_title>A Study Paclitaxel With Without Ramucirumab ( LY3009806 ) Participants With Gastric Gastroesophageal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Ramucirumab</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Have Eastern Cooperative Oncology Group Performance Status ( ECOGPS ) 0 1 study entry . Have histopathologically cytologically confirm diagnosis gastric gastroesophageal junction ( GEJ ) adenocarcinoma . Have metastatic disease locally advance , unresectable disease . Have least 1 measurable lesion base Response Evaluation Criteria Solid Tumors ( RECIST ) , Version 1.1 . Have experience document objective radiographic symptomatic disease progression firstline therapy , within 4 month last dose firstline therapy platinum/fluoropyrimidine doublet unresectable metastatic disease . Have adequate organ function . Have urinary protein ≤1+ dipstick routine urinalysis . Have undergone major surgery within 28 day prior randomization . Have receive firstline chemotherapy platinum fluoropyrimidine without anthracycline advance gastric GEJ adenocarcinoma . Have receive previous systemic therapy ( include investigational agent ) target vascular endothelial growth factor ( VEGF ) VEGF receptor signal pathway . Have history deep vein thrombosis , pulmonary embolism , significant thromboembolism 3 month prior randomization . Have significant bleeding disorder , vasculitis , significant bleeding episode gastrointestinal ( GI ) tract within 3 month prior study entry . Have history GI perforation and/or fistula within 6 month prior randomization . Have experience arterial thromboembolic event within 6 month prior randomization . Have uncontrolled arterial hypertension ( systolic blood pressure ≥160 millimeter mercury [ mmHg ] diastolic blood pressure ≥100 mmHg ) despite standard medical management . Have serious nonhealing wound , peptic ulcer , bone fracture within 28 day prior randomization . Have serious illness medical condition ( ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Second line</keyword>
	<keyword>Angiogenesis</keyword>
	<keyword>Vascular endothelial growth factor receptor 2</keyword>
</DOC>